III. Contraindications

  1. See Fibric Acid Derivative
  2. Avoid in Serum Creatinine >=2 mg/dl

IV. Dosing

  1. Take 600 mg orally twice daily at 30 minutes before meals

V. Efficacy

  1. See Fibric Acid Derivative
  2. No Fibrate has been shown to reduce all cause mortality
  3. Gemfibrozil is the only Fibrate shown to decrease cardiovascular events
    1. NNT to prevent one coronary event: 46-125

VI. Adverse Effects

VII. Safety

  1. Pregnancy Category C
  2. Unknown safety in Lactation

VIII. Drug Interactions

  1. See Fibric Acid Derivative
  2. Avoid with specific other medications
    1. Statins (esp. Simvastatin)
    2. Dasabuvir
    3. Repaglinide
  3. Increases levels of other medications
    1. CYP2C8 Substrates (e.g. Montelukast, Paclitaxel, Pioglitazone)
    2. OATP1B1 Substrates (e.g. Ezetimibe, Glyburide, Olmesartan, Rifampin)
    3. Warfarin

Images: Related links to external sites (from Bing)

Related Studies

Cost: Medications

gemfibrozil (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing)
GEMFIBROZIL 600 MG TABLET Generic $0.10 each

Ontology: Gemfibrozil (C0017245)

Definition (NCI) A fibric acid derivative with hypolipidemic effects. Gemfibrozil interacts with peroxisome proliferator-activated receptors (PPARalpha) resulting in PPARalpha-mediated stimulation of fatty acid oxidation and an increase in lipoprotein lipase (LPL) synthesis. This enhances triglyceride-rich lipoprotein clearance and reduces the expression of apolipoprotein C-III (apoC-III). The reduction in hepatic production of apoC-III results in subsequent reduction of serum levels of very-low-density-lipoprotein cholesterol (VLDL-C). In addition, gemfibrozil-mediated PPARalpha stimulation of apoA-I and apoA-II expression results in an increase in high-density lipoprotein cholesterol (HDL-C).
Definition (MSH) A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol.
Definition (CSP) lipid regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol.
Concepts Pharmacologic Substance (T121) , Lipid (T119)
MSH D015248
SnomedCT 35282000, 387189002
LNC LP15168-5, MTHU002557
English Gemfibrozil, Gemfibrosil, Pentanoic acid, 5-(2,5-dimethylphenoxy)-2,2-dimethyl-, gemfibrozil, gemfibrozil (medication), gemfibrozil (Lopid), GEMFIBROZIL, Gemfibrozil [Chemical/Ingredient], gemfibrosil, Gemfibrozil product, Gemfibrozil (product), Gemfibrozil (substance)
Swedish Gemfibrozil
Czech gemfibrozil
Finnish Gemfibrotsiili
Russian GEMFIBROZIL, ГЕМФИБРОЗИЛ
Japanese ジェムフィブロジィル, ゲムフィブロジル, ゲンフィブロジル
Spanish genfibrocil (producto), gemfibrozilo (producto), genfibrocil, Gemfibrozil, gemfibrozilo (sustancia), gemfibrozilo, gemfibrozil, genfibrocil (sustancia), Gemfibrozilo
Italian Gemfibrosil, Gemfibrozil
French Gemfibrosil, Gemfibrozil
Polish Gemfibrozil
Croatian Gemfibrozil
Portuguese Genfibrozil, Genfibrozila
German Gemfibrozil